TRML · Tourmaline Bio
Acquired Company
Novartis completed the acquisition of Tourmaline Bio, Inc., and Tourmaline became an indirect wholly owned subsidiary of Novartis.
Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions, with a particular emphasis on autoimmune disorders and oncology. Leveraging its proprietary technology platform, the company has established a robust pipeline of innovative therapies designed to meet critical unmet medical needs in the realm of precision medicine. With a strong commitment to scientific excellence and strategic collaborations, Tourmaline Bio is well-positioned to capitalize on transformative growth opportunities within the biopharmaceutical sector, making it an attractive investment prospect for institutional investors.
Market Cap
1.233B
52 Wk Range
$47.81 - $48.00
Previous Close
$47.98
Open
$47.98
Volume
N/A
Day Range
$47.98 - $47.98
Enterprise Value
990.8M
Cash
31.42M
Avg Qtr Burn
-20.26M
Insider Ownership
14.62%
Institutional Own.
89.13%
Qtr Updated
Jun 30th 2025
